secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalyn Pharma Inc. (AVLN)
CIK:        0001540171
Form:       8-K
Filed at:   2026-06-03T11:25:05+00:00
Accession:  0001193125-26-254581
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalyn Pharma reports Q1 net loss of $26.9M; MIST Phase 2b enrollment on track
------------------------------------------------------------------------------

- Net loss of $26.9M in Q1 2026 vs $17.5M in Q1 2025; R&D expense rose to $22.9M.
- Cash, equivalents and marketable securities of $123.1M as of March 31, 2026; excludes $316.1M net IPO proceeds raised in May 2026.
- MIST Phase 2b trial of AP01 in PPF enrollment on schedule to complete mid-2026; topline data expected H2 2027.
- AURA Phase 2 trial of AP02 in IPF underway; first patient dosed March 2026; topline data expected late 2027.
- Appointed Adam Golden as General Counsel and Head of BD, and Frank Salisbury as SVP Commercial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/0001193125-26-254581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/ck0001540171-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-254581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer